Skip to main content

David Charles Montefiori, PhD

Professor of Surgery
Office: Surgical Oncology Res Fac, Durham, NC 27710
Campus Mail: DUMC Box 2926 Med Ctr, Durham, NC 27710

Dr. Montefiori is Professor and Director of the Laboratory for AIDS Vaccine Research and Development in the Department of Surgery, Division of Surgical Sciences, Duke University Medical Center. His major research interests are viral immunology and AIDS vaccine development, with a special emphasis on neutralizing antibodies. One of his highest priorities is to identify immunogens that generate broadly cross-reactive neutralizing antibodies for inclusion in HIV vaccines.  Many aspects of the neutralizing antibody response are studied in his laboratory, including mechanisms of neutralization and escape, epitope diversity among genetic subtypes and geographic origins, ontogeny of broadly neutralizing antibody responses and computationally-assisted vaccine design. Over the years he has explored multiple types of assays for neutralizing antibodies and other potential antiviral antibodies, focusing on assay optimization, standardization, validation and high throughput. The scope of research covers HIV-infected individuals and nonhuman primate models of simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) infection.  Dr. Montefiori also directs a large AIDS vaccine immune monitoring program, which operates in compliance with Good Clinical Laboratory Practice and has served as a national and international resource for standardized assessments of neutralizing antibody responses in preclinical and clinical trials of candidate AIDS vaccines since 1988. In 2002 he chaired the Antibody Laboratory Standardization Working Group that assisted in the design of the Global HIV Vaccine Enterprise Strategic Plan for HIV vaccines. He currently directs the Core Neutralizing Antibody Laboratories for the HIV Vaccine Clinical Trials Network (HVTN), the NIH Preclinical HIV-1 Vaccine Program and the Center for HIV/AIDS Vaccine Immunology- Immunogen Design (CHAVI-ID). He also directs a large Comprehensive Antibody Vaccine Immune Monitoring Consortium (CAVIMC) as part of the Bill and Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery (CAVD). He has published over 500 original research papers that have helped shape the scientific rationale for antibody-based HIV-1 vaccines.

Education and Training

  • Ph.D., Clemson University, 1982

Publications

Wu, Fan, Ilnour Ourmanov, Andrea Kirmaier, Sivan Leviyang, Celia LaBranche, Jinghe Huang, Sonya Whitted, Kenta Matsuda, David Montefiori, and Vanessa M. Hirsch. “SIV infection duration largely determines broadening of neutralizing antibody response in macaques.” J Clin Invest, July 14, 2020. https://doi.org/10.1172/JCI139123.

Full Text

De Rosa, Stephen C., Srilatha Edupuganti, Yunda Huang, Xue Han, Marnie Elizaga, Edith Swann, Laura Polakowski, et al. “Robust antibody and cellular responses induced by DNA-only vaccination for HIV.” Jci Insight 5, no. 13 (July 9, 2020). https://doi.org/10.1172/jci.insight.137079.

Full Text

Korber, Bette, Will M. Fischer, Sandrasegaram Gnanakaran, Hyejin Yoon, James Theiler, Werner Abfalterer, Nick Hengartner, et al. “Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.” Cell, July 3, 2020. https://doi.org/10.1016/j.cell.2020.06.043.

Full Text

Shao, Shuai, Wei-Chiao Huang, Cuiyan Lin, Mark D. Hicar, Celia C. LaBranche, David C. Montefiori, and Jonathan F. Lovell. “An Engineered Biomimetic MPER Peptide Vaccine Induces Weakly HIV Neutralizing Antibodies in Mice.” Ann Biomed Eng 48, no. 7 (July 2020): 1991–2001. https://doi.org/10.1007/s10439-019-02398-8.

Full Text

Tuyishime, Marina, Carolina Garrido, Shalini Jha, Matthew Moeser, Dieter Mielke, Celia LaBranche, David Montefiori, et al. “Improved Killing of HIV-infected Cells Using Three Neutralizing and Non-neutralizing Antibodies.” J Clin Invest, June 25, 2020. https://doi.org/10.1172/JCI135557.

Full Text

Kasturi, Sudhir Pai, Mohammed Ata Ur Rasheed, Colin Havenar-Daughton, Mathew Pham, Traci Legere, Zarpheen Jinnah Sher, Yevgeny Kovalenkov, et al. “3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates.” Sci Immunol 5, no. 48 (June 19, 2020). https://doi.org/10.1126/sciimmunol.abb1025.

Full Text

Lewis, Phoebe E., Ethan C. Poteet, Dongliang Liu, Changyi Chen, Celia C. LaBranche, Sherry A. Stanfield-Oakley, David C. Montefiori, Guido Ferrari, and Qizhi Yao. “CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses.” Vaccines (Basel) 8, no. 2 (June 6, 2020). https://doi.org/10.3390/vaccines8020284.

Full Text

Lévy, Yves, Christine Lacabaratz, Kim Ellefsen-Lavoie, Wolfgang Stöhr, Jean-Daniel Lelièvre, Pierre-Alexandre Bart, Odile Launay, et al. “Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.” Plos Pathog 16, no. 6 (June 2020): e1008522. https://doi.org/10.1371/journal.ppat.1008522.

Full Text

Arunachalam, Prabhu S., Tysheena P. Charles, Vineet Joag, Venkata S. Bollimpelli, Madeleine K. D. Scott, Florian Wimmers, Samantha L. Burton, et al. “T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers.” Nat Med 26, no. 6 (June 2020): 932–40. https://doi.org/10.1038/s41591-020-0858-8.

Full Text

Felber, Barbara K., Zhongyan Lu, Xintao Hu, Antonio Valentin, Margherita Rosati, Christopher A. L. Remmel, Joshua A. Weiner, et al. “Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge.” Cell Rep 31, no. 6 (May 12, 2020): 107624. https://doi.org/10.1016/j.celrep.2020.107624.

Full Text

Pages